Table 58. Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 2010[1]

Reporting Area	Total Cases with Therapy Extended[2,3]	Reasons Therapy Was Extended											
		Rifampin Resistant		Adverse Event		Non-adherence		Failure		Clinically Indicated		Other	
		No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)
United States	**766**	**72**	**(9.4)**	**156**	**(20.4)**	**104**	**(13.6)**	**7**	**(0.9)**	**330**	**(43.1)**	**211**	**(27.5)**
Alabama	4	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	4	(100.0)	0	(0.0)
Alaska	4	3	(75.0)	2	(50.0)	2	(50.0)	1	(25.0)	0	(0.0)	0	(0.0)
Arizona	7	0	(0.0)	1	(14.3)	0	(0.0)	0	(0.0)	5	(71.4)	2	(28.6)
Arkansas	4	0	(0.0)	1	(25.0)	2	(50.0)	0	(0.0)	1	(25.0)	0	(0.0)
California	228	16	(7.0)	59	(25.9)	20	(8.8)	0	(0.0)	105	(46.1)	73	(32.0)
Colorado	4	0	(0.0)	1	(25.0)	1	(25.0)	0	(0.0)	1	(25.0)	1	(25.0)
Connecticut	10	1	(10.0)	3	(30.0)	1	(10.0)	0	(0.0)	4	(40.0)	6	(60.0)
Delaware	1	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(100.0)
District of Columbia	1	0	(0.0)	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Florida	41	6	(14.6)	9	(22.0)	3	(7.3)	1	(2.4)	22	(53.7)	6	(14.6)
Georgia	37	4	(10.8)	1	(2.7)	12	(32.4)	0	(0.0)	22	(59.5)	7	(18.9)
Hawaii	3	0	(0.0)	1	(33.3)	0	(0.0)	0	(0.0)	0	(0.0)	3	(100.0)
Idaho	1	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(100.0)	0	(0.0)
Illinois	23	1	(4.3)	8	(34.8)	2	(8.7)	1	(4.3)	11	(47.8)	1	(4.3)
Indiana	4	0	(0.0)	1	(25.0)	1	(25.0)	0	(0.0)	1	(25.0)	2	(50.0)
Iowa	0	0	...	0	...	0	...	0	...	0	...	0	...
Kansas	0	0	...	0	...	0	...	0	...	0	...	0	...
Kentucky	1	0	(0.0)	1	(100.0)	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)
Louisiana	13	0	(0.0)	3	(23.1)	2	(15.4)	0	(0.0)	2	(15.4)	6	(46.2)
Maine	0	0	...	0	...	0	...	0	...	0	...	0	...
Maryland	13	0	(0.0)	1	(7.7)	3	(23.1)	0	(0.0)	6	(46.2)	4	(30.8)
Massachusetts	15	1	(6.7)	7	(46.7)	0	(0.0)	1	(6.7)	6	(40.0)	1	(6.7)
Michigan	11	0	(0.0)	0	(0.0)	4	(36.4)	0	(0.0)	3	(27.3)	4	(36.4)
Minnesota	15	0	(0.0)	4	(26.7)	3	(20.0)	0	(0.0)	8	(53.3)	1	(6.7)
Mississippi	4	1	(25.0)	2	(50.0)	0	(0.0)	0	(0.0)	1	(25.0)	0	(0.0)
Missouri	0	0	...	0	...	0	...	0	...	0	...	0	...
Montana	0	0	...	0	...	0	...	0	...	0	...	0	...
Nebraska	2	0	(0.0)	1	(50.0)	0	(0.0)	0	(0.0)	1	(50.0)	0	(0.0)
Nevada	9	2	(22.2)	4	(44.4)	1	(11.1)	0	(0.0)	3	(33.3)	1	(11.1)
New Hampshire	1	0	(0.0)	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
New Jersey	23	8	(34.8)	6	(26.1)	1	(4.3)	0	(0.0)	6	(26.1)	10	(43.5)
New Mexico	3	1	(33.3)	1	(33.3)	1	(33.3)	0	(0.0)	0	(0.0)	0	(0.0)

Table 58. (Con't) Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 2010[1]

Reporting Area	Total Cases with Therapy Extended[2,3]	Reasons Therapy Was Extended											
		Rifampin Resistant		Adverse Event		Non-adherence		Failure		Clinically Indicated		Other	
		No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)
New York State[4]	21	6	(28.6)	3	(14.3)	1	(4.8)	0	(0.0)	7	(33.3)	5	(23.8)
New York City	17	3	(17.6)	3	(17.6)	4	(23.5)	0	(0.0)	4	(23.5)	5	(29.4)
North Carolina	18	0	(0.0)	5	(27.8)	2	(11.1)	0	(0.0)	10	(55.6)	5	(27.8)
North Dakota	2	0	(0.0)	1	(50.0)	1	(50.0)	0	(0.0)	0	(0.0)	0	(0.0)
Ohio	7	1	(14.3)	1	(14.3)	0	(0.0)	0	(0.0)	6	(85.7)	0	(0.0)
Oklahoma	4	0	(0.0)	2	(50.0)	0	(0.0)	0	(0.0)	0	(0.0)	2	(50.0)
Oregon	1	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Pennsylvania	32	4	(12.5)	13	(40.6)	2	(6.3)	0	(0.0)	13	(40.6)	11	(34.4)
Rhode Island	9	0	(0.0)	0	(0.0)	4	(44.4)	0	(0.0)	6	(66.7)	1	(11.1)
South Carolina	7	0	(0.0)	2	(28.6)	1	(14.3)	0	(0.0)	4	(57.1)	0	(0.0)
South Dakota	0	0	...	0	...	0	...	0	...	0	...	0	...
Tennessee	12	0	(0.0)	0	(0.0)	1	(8.3)	0	(0.0)	6	(50.0)	6	(50.0)
Texas	110	7	(6.4)	4	(3.6)	25	(22.7)	2	(1.8)	47	(42.7)	27	(24.5)
Utah	2	1	(50.0)	1	(50.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)
Vermont	0	0	...	0	...	0	...	0	...	0	...	0	...
Virginia	18	1	(5.6)	2	(11.1)	0	(0.0)	0	(0.0)	5	(27.8)	10	(55.6)
Washington	15	2	(13.3)	0	(0.0)	2	(13.3)	0	(0.0)	4	(26.7)	7	(46.7)
West Virginia	0	0	...	0	...	0	...	0	...	0	...	0	...
Wisconsin	8	2	(25.0)	0	(0.0)	1	(12.5)	1	(12.5)	5	(62.5)	2	(25.0)
Wyoming	1	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	0	(0.0)	1	(100.0)
American Samoa[5]	0	0	...	0	...	0	...	0	...	0	...	0	...
Fed. States of Micronesia[5]	3	1	(33.3)	1	(33.3)	0	(0.0)	0	(0.0)	0	(0.0)	1	(33.3)
Guam[5]	2	0	(0.0)	0	(0.0)	1	(50.0)	0	(0.0)	1	(50.0)	0	(0.0)
Marshall Islands[5]	1	0	(0.0)	0	(0.0)	1	(100.0)	0	(0.0)	0	(0.0)	0	(0.0)
N. Mariana Islands[5]	0	0	...	0	...	0	...	0	...	0	...	0	...
Puerto Rico[5]	0	0	...	0	...	0	...	0	...	0	...	0	...
Republic of Palau[5]	0	0	...	0	...	0	...	0	...	0	...	0	...
U.S. Virgin Islands[5]	0	0	...	0	...	0	...	0	...	0	...	0	...

[1] Most recent year for which data are available.
[2] Among patients who were alive at diagnosis, started on treatment and had a duration of treatment greater than 365 days.
[3] Patient may have more than 1 reason therapy was extended beyond 12 months (total reasons therapy extended may be greater than total patients with therapy extended).
[4] Excludes New York City.
[5] Not included in U.S. totals.
Note: Ellipses indicate data not available.